Ekso bionics' acceptance into nvidia connect program bears early fruit

Ai voice agent for user interface being designed to support exoskeleton device operation, motivation, training, and safety first proof-of-concept demonstration comes just over a month after company announced its acceptance into the nvidia connect program san rafael, calif., june 18, 2025 (globe newswire) -- ekso bionics holdings, inc. (nasdaq: ekso) (“ekso bionics” or the “company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that it has successfully demonstrated initial proof-of-concept in integrating artificial intelligence (“ai”)-enabled capabilities across its portfolio of enterprise health and personal health exoskeleton devices.
EKSO Ratings Summary
EKSO Quant Ranking